Spring Bank reports agreement for HBV antisense oligonucleotide compounds
Spring Bank Pharmaceuticals announced that it has entered into a research agreement with The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to evaluate Spring Bank's hepatitis B virus antisense oligonucleotide compounds.Spring Bank has entered into a non-clinical evaluation agreement to access NIAID's preclinical services program to further evaluate Spring Bank's HBV antisense oligonucleotide compounds. Under the agreement, NIAID-funded contractors will evaluate Spring Bank's lead compounds in the HBV transgenic mouse model, a well-established preclinical model to assess compound efficacy. NIAID has previously supported the evaluation of several of Spring Bank's HBV antisense oligonucleotide compounds in antiviral in vitro assays. Spring Bank retains exclusive rights to these compounds. "We are grateful to NIAID for their support of our HBV oligonucleotide antisense program," said Kris Iyer, Ph.D., Chief Scientific Officer and Co-Founder of Spring Bank. "The research supported by this prestigious institution will enhance our knowledge of the non-clinical efficacy profile for our HBV antisense oligonucleotide R&D program."